Table 1.

Demographic and neuropathological data

Case	f/m	age	brain wt	NFT	Aβ	α-syn	TDP-43	APOE	Diagnoses
1	f	55	1455	I	0	0	−	ε3/4	intraventricular hemorrhage
2	m	55	1780	I	0	0	−	ε3/3	bronchopneumonia
3	f	50	1293	I	0	0	−	ε3/3	PCOM aneurysm, SAB
4	m	50	1600	I	0	0	−	ε4/4	M. Werlhof, hepatitis C
5	f	72	1070	I	3	0	−	ε3/4	cardiac failure
6	f	79	1165	I	0	0	−	ε3/3	coronary artery disease
7	f	93	1090	III (IV)	2	0	−	na	craniocerebral trauma
8	m	68	1380	III	0	0	−	na	aspiration pneumonia
9	m	72	1500	III	0	0	−	ε3/4	cardiac failure
10	m	74	1465	III	0	0	−	ε4/4	malignant neoplasm
11	m	76	1520	III	4	0	+	na	pneumonia
12	f	81	1130	III	2	0	−	ε3/3	acute myeloid leukemia
13	f	88	1495	III	3	0	−	ε3/4	cerebral hemorrhage parietooccipital
14	m	84	1170	V (VI)	3	0	+	ε3/4	AD
15	f	84	1175	V	3	2	+	ε3/3	AD, ILBD
16	m	58	1335	V	2	0	−	ε3/4	AD, myocardial infarction
17	f	72	1185	V	4	0	−	ε3/3	AD, craniocerebral trauma after falling
18	f	76	1405	V	4	0	−	ε3/4	AD, craniocerebral trauma after falling
19	m	76	1205	V	5	0	−	na	AD, cardiac failure
20	m	78	1460	V	5	0	−	ε3/4	AD
Control 21	f	30	1315	0	0	0	−	ε3/3	malignant neoplasm

20 cases fall into three NFT groups: NFT stage I (4 females, 2 males, 50–79 years); NFT stage III (3 females, 4 males, 68–93 years); NFT stage V (3 females, 4 males, 58–84 years). Abbreviations: f, m—female, male; age—age in years; brain wt—fresh brain weight in grams; NFT—Alzheimer's disease-related neurofibrillary tangle stage using Gallyas silver-iodide staining; Aβ—amyloid-β deposition phase using 4G8 IHC; α-syn—Parkinson disease-related neuropathological stage using α-synuclein IHC; TDP-43—43-kDa TAR DNA-binding protein neuronal inclusions; APOE—APOE allele status; n/a -not available; AD—Alzheimer's disease; ILBD—incidental Lewy body disease; PCOM -posterior communicating artery; SAB—subarachnoid bleeding